Scholars Central

Conference abstractPublished 17 Dec 2014

Safety and quality assurance of chemotherapeutic preparations in a hospital production unit: Acceptance sampling plan and economic impact

Authors: Angelo Paci

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The drug supply chain in hospital composed of successive steps: drug prescription is a medical task; preparation and dispensation are pharmaceutical ones, whereas drug administration belongs to nurses. Potential errors such as wrong dosage, solvent?s errors, wrong labeling or, in some exceptional cases, chemotherapeutic active substances? errors can occur, leading to potential risks of morbidity and mortality for patients. Recommendations and quality assurance processes have since been applied to ensure safety at each stage of the drug supply chain. The pharmacist is responsible for procurement, distribution, surveillance, and control of all drugs used in the hospital. Drug preparation and quality control are also mandatory activities for a hospital pharmacy. By allowing the identification of qualitative and quantitative preparation non-conformity, verification of the finished product contributes to ensuring drug supply chain safety. However, these quality controls were rare in the hospital pharmacy setting. In 2002, a study showed that only 4.7% of American pharmacies compounding cytotoxic preparations performed these controls and were thus compliant with 2000 ASHP guidelines on quality assurance for pharmacy-prepared sterile products. Since 1998, our clinical pharmacy department has been equipped with an analytical platform using high performance thin-layer chromatography (HPTLC), high performance liquid chromatography (HPLC) and spectrophotometry (IRTF-UV) to ensure post-production quality control of chemotherapeutic preparations, both qualitatively (identification) and quantitatively (concentration). In 2003, a sampling plan was defined to reduce the number of chemotherapy quality controls while preserving the same level of quality. Recent qualitative and quantitative changes led us to define a second sampling plan supplemented by an economic evaluation to determine the cost and cost-savings of quality control. The study considers preparation produced during four semesters classified into three groups. The first one includes drugs produced below 200 batches a semester. Group 2, those for which the lot of preparation lots would have been rejected twice among these four semesters. Group 3, those would have been accepted). A single sampling plan by attributes was applied with an acceptance quality level of 1.65% and a lot tolerance percent defective below 5%. A micro-costing study was conducted on quality control, from the sampling to the validation of the results. Among 39 cytotoxic drugs, 11 were sampled which enabled to avoid a mean of 17,512 control assays per year. Each batch of the 28 non-sampled drugs was however analyzed. Costs were estimated at 4USD and 7USD for control assays depending of the analytical method.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Pharmacology & Biopharmaceutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Angelo Paci”